EN DE
Watch Japan Vietnam Medical Instrument JSC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Japan Vietnam Medical Instrument JSC (JVC) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Japan Vietnam Medical Instrument JSC stock VND 2,348, price VND 2,640, that is 11.1% below the price, quality 50 out of 100. Rating: overvalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare VN · ISIN VN000000JVC7

JV Japan Vietnam Medical Instrument JSC logo Thin data Nov 4, 2026

Japan Vietnam Medical Instrument JSC

JVC · VN
Expensive, in a downtrend

Our calculation puts a fair price 11% below what the stock costs today.

Generates free cash flow
Ranks above peers (8/12)
Costs just 6.4 times its yearly profit.
Quality 50/100
Thin margins · 6.8% net margin (TTM)
Fair value 2,348 VND · Overvalued
Weak Growth (revenue YoY −4.9 %/yr in VND)
Narrow moat 38/100 · thin data
Thin data
Watch Japan Vietnam Medical Instrument JSC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

13,450 VND 2,310 VND Fair Value 2,348 VND Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 2,310 VND – 13,450 VND · fair‑value band 2,087 VND – 2,824 VND · the 2,640 VND price screens above the 2,348 VND fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Japan Vietnam Medical Instrument JSC in your weekly email

Every Wednesday you see whether Japan Vietnam Medical Instrument JSC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vietnam Medical and Pharmaceutical Investment Joint Stock Company engages in the distribution of medical equipment and instruments in Vietnam.

Show moreShow less

The company distributes medical equipment, including diagnostic imaging products, such as magnetic resonance imaging (MRI), computed tomography (CT), X-ray system, computed and direct radiography, dry imager, contrast injector, PET/CT imaging system, and diagnostic ultrasound products; washers, dryers, and sterilizers; and ultrasound systems, anesthesia and breathing machines, syringe and infusion pumps, and patient monitors, as well as navigation products.

It also offers SD-S, DI-HT, SD-Q, and DI-HL dry medical films; central venous catheters and invasive blood pressure transducers for resuscitation-cardiovascular intervention; Scepter XC and C balloon, and Chaperon guiding catheters; LVIS Jr. and LVIS coil assist stents; and V-grip detachment controllers, Traxcess guidewires, Headway Duo microcatheters, ERIC retrieval devices, SOFIA PLUS aspiration and SOFIA intermediate catheters, FRED and FRED Jr. flow diversion devices, platinum and hydrogel coils, PHIL liquid embolics, and Headway microcatheters.

In addition, the company provides technical services, such as consulting, technical support, repair, and maintenance services; and IT services for hospitals.

Further, it leases medical equipment and instruments; operates general, specialist, and dental clinics; invests in medical equipment; and engages in the financial investment activities.

Vietnam Medical and Pharmaceutical Investment Joint Stock Company was formerly known as Japan Vietnam Medical Investment and Development Joint Stock Company and changed its name to Vietnam Medical and Pharmaceutical Investment Joint Stock Company in November 2025.

The company was founded in 2001 and is headquartered in Hanoi, Vietnam.

Stock analysis

Japan Vietnam Medical Instrument JSC (JVC) currently trades at 2,640 VND, while our model-based Fair Value estimate is 2,348 VND, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 4,639 VND per share, and 4 of the 11 models we run sit above the 2,640 VND price.

Bear case: the Asset-Based group reads lowest at 1,292 VND, and 7 of the 11 models stay below the price. Data coverage for this calculation is low.

Scenario range: 2,087 VND (bear) to 2,824 VND (bull), the price of 2,640 VND sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Japan Vietnam Medical Instrument JSC reported revenue of 391B VND in FY2022 versus 517B VND in FY2020, a compound −13.0%/yr. Reported net income was −29.9B VND in FY2022.

Key figures

Market cap 297B VND (≈ $11.6M) Micro · P/E ratio 6.0 · P/S ratio 0.43 · EPS (TTM) 443.44 VND · Net margin 6.8% · Return on equity 8.1% · Return on assets (EBIT) −6.7% (3-year average) · Operating margin 14.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −11%, JVC screens cheaper than that median.

Fair Value models

Bear 2,087 VND Fair Value 2,348 VND Bull 2,824 VND
Price 2,640 VND · Downside -11.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 2,066 VND 2,289 VND 2,645 VND 73
Growth DCF 2,087 VND 2,296 VND 2,605 VND 70
Owner Earnings 4,491 VND 5,324 VND 6,655 VND 68
All 11 models by family
DCF Models
FCF DCF 2,066 VND 2,289 VND 2,645 VND 73
Owner Earnings 4,491 VND 5,324 VND 6,655 VND 68
5Y Revenue Exit 2,020 VND 2,348 VND 2,824 VND 65
5Y EBITDA Exit 3,497 VND 4,900 VND 6,756 VND 66
10Y Revenue Exit 2,021 VND 2,237 VND 2,462 VND 60
10Y EBITDA Exit 2,794 VND 3,565 VND 4,401 VND 61
Multiples
EV/EBITDA 5,440 VND 6,860 VND 8,280 VND 64
EV/Revenue 2,047 VND 2,419 VND 2,791 VND 52
Asset-Based
NCAV (Graham) 852.43 VND 1,292 VND 1,614 VND 52
Growth DCF
Growth DCF 2,087 VND 2,296 VND 2,605 VND 70
Rev-Margin DCF 2,020 VND 2,373 VND 2,812 VND 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 63
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Vietnam: IMF forecast 4.1% a year to 2030, 3.1% from 2016 to 2025) that is about +13.2% a year for the price.

JVC screens overvalued: fair value 11% below the price. Compare with Abbott Laboratories, →

Compare Japan Vietnam Medical Instrument JSC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −17.0% · Above median
Profitability
Return on equity (12 months) 8.1% · Above median
Return on assets −5.0% · Below median
Net margin (12 months) 6.8% · Above median
Operating margin (12 months) 14.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 4.5% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 6.0× · Cheapest 25%
P/B 0.75× · Cheapest 25%
P/S (12 months) 0.43× · Cheapest 25%
Price / free cash flow (fiscal year) 29.7× · Pricier than median
EV/EBITDA 2.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 6
FUTURE (revenue growth)23 · sector 36
PAST (return on equity)33 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs JVC
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs JVC
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs JVC
DexCom, Inc DXCM $79.41 $87.35 +10% vs JVC
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs JVC
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs JVC
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs JVC
Abbott Laboratories, ABT $109.93 $75.28 −32% vs JVC
Medtronic plc MDT $101.80 $65.61 −36% vs JVC
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs JVC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Japan Vietnam Medical Instrument JSC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Japan Vietnam Medical Instrument JSC Fair Value". https://www.fairvalue-calculator.com/stock/JVC

Frequently asked questions

Is Japan Vietnam Medical Instrument JSC (JVC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 2,348 VND versus a price of 2,640 VND, about 11% lower (overvalued).
What is the fair value of JVC?
Our model-based fair value for Japan Vietnam Medical Instrument JSC is 2,348 VND (as of Nov 4, 2026), built from audited fundamentals. The current price: 2,640 VND.
What is the quality score of JVC?
Japan Vietnam Medical Instrument JSC has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Japan Vietnam Medical Instrument JSC (JVC)?
Our model-based price target is the fair value of 2,348 VND (as of Nov 4, 2026) from 11 valuation models. Cautious scenario 2,087 VND, optimistic scenario 2,824 VND. It is a calculation from audited fundamentals, not an analyst target.
What is the Japan Vietnam Medical Instrument JSC stock forecast for 2026?
Our models put fair value at 2,348 VND, about 11% lower versus a price of 2,640 VND (overvalued). Cautious scenario 2,087 VND, optimistic scenario 2,824 VND. The calculation is refreshed regularly with new filings.
What is the revenue of Japan Vietnam Medical Instrument JSC (JVC)?
Japan Vietnam Medical Instrument JSC reported trailing-twelve-month revenue of about 747B VND (latest available figure, as of Nov 4, 2026).
What growth is priced into Japan Vietnam Medical Instrument JSC (JVC)?
For today's price to be fair in a discounted-cash-flow model, Japan Vietnam Medical Instrument JSC would have to grow free cash flow by +17.8 % per year for five years (discount rate 12.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 2 years revenue grew -13.0 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of JVC use?
Our models discount Japan Vietnam Medical Instrument JSC at 12.8 %: a base by market capitalisation (nano), damped by beta 0.83, country premium for Vietnam. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Japan Vietnam Medical Instrument JSC that is +17.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.8 %) and the same formula as our fair value.
How much growth has Japan Vietnam Medical Instrument JSC (JVC) delivered so far?
Over the past 2 years revenue at Japan Vietnam Medical Instrument JSC grew -13.0 % a year. The price currently implies free-cash-flow growth of +17.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Japan Vietnam Medical Instrument JSC (JVC) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Japan Vietnam Medical Instrument JSC (+17.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Japan Vietnam Medical Instrument JSC (JVC)?
The free-cash-flow yield on the price is 3.61 %: that much free cash flow Japan Vietnam Medical Instrument JSC produces per unit of market value. When it exceeds the discount rate of our models (12.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Japan Vietnam Medical Instrument JSC (JVC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Japan Vietnam Medical Instrument JSC it is 2,348 VND per share (as of Nov 4, 2026), against a price of 2,640 VND. It is the blended result of 11 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Japan Vietnam Medical Instrument JSC stock overvalued or undervalued in 2026?
As of Nov 4, 2026, JVC trades above its calculated fair value: price 2,640 VND, fair value 2,348 VND, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JVC?
No. The price is what the market pays today (2,640 VND); the fair value is what the company's own numbers justify (2,348 VND). For Japan Vietnam Medical Instrument JSC the two are 291.99 VND per share apart. That gap is exactly why we show both numbers side by side.
How much is Japan Vietnam Medical Instrument JSC worth?
The market values Japan Vietnam Medical Instrument JSC at about 297B VND (market capitalisation, as of Nov 4, 2026). Per share that is 2,640 VND; our models calculate a fair value of 2,348 VND per share.
What do the bullish and bearish scenarios say about JVC?
Our models span a range for Japan Vietnam Medical Instrument JSC: cautious scenario 2,087 VND, base 2,348 VND, optimistic 2,824 VND per share (as of Nov 4, 2026, price 2,640 VND). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JVC?
Japan Vietnam Medical Instrument JSC trades at a price-to-earnings ratio of 6.0 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,348 VND is built from several models across several years. Other multiples: P/B 0.8, P/S 0.4, EV/EBITDA 2.1.
How solid is the balance sheet of Japan Vietnam Medical Instrument JSC (JVC)?
Balance-sheet figures for Japan Vietnam Medical Instrument JSC (as of Nov 4, 2026): return on equity 8.1%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is JVC from its 52-week high?
Japan Vietnam Medical Instrument JSC trades at 2,640 VND, about 66% below its 52-week high of 7,770 VND and 6% above the low of 2,480 VND (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2,348 VND is for.
Which stocks are comparable to Japan Vietnam Medical Instrument JSC?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Japan Vietnam Medical Instrument JSC stock attractive at the current price?
The data as of Nov 4, 2026: price 2,640 VND, calculated fair value 2,348 VND (−11%), Quality Score 50/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JVC calculated?
We run Japan Vietnam Medical Instrument JSC through 11 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 2,348 VND builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Japan Vietnam Medical Instrument JSC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Japan Vietnam Medical Instrument JSC (JVC)?
The closing price on Nov 9, 2026 was 2,640 VND. Our model-based fair value is 2,348 VND, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Japan Vietnam Medical Instrument JSC right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Japan Vietnam Medical Instrument JSC

How large is the market capitalisation of Japan Vietnam Medical Instrument JSC (JVC)?
The market capitalisation of Japan Vietnam Medical Instrument JSC is 297B VND (≈ $11.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Japan Vietnam Medical Instrument JSC (JVC)?
The price-to-sales ratio of Japan Vietnam Medical Instrument JSC is 0.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Japan Vietnam Medical Instrument JSC (JVC)?
Earnings per share at Japan Vietnam Medical Instrument JSC are 443.44 VND (price ÷ EPS = P/E 6.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Japan Vietnam Medical Instrument JSC (JVC)?
The net margin of Japan Vietnam Medical Instrument JSC is 6.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Japan Vietnam Medical Instrument JSC (JVC)?
The return on equity (ROE) of Japan Vietnam Medical Instrument JSC is 8.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Japan Vietnam Medical Instrument JSC (JVC)?
On an EBIT basis the return on assets of Japan Vietnam Medical Instrument JSC is −6.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Japan Vietnam Medical Instrument JSC (JVC)?
The operating margin of Japan Vietnam Medical Instrument JSC is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Japan Vietnam Medical Instrument JSC (JVC)?
Revenue at Japan Vietnam Medical Instrument JSC is growing +4.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Japan Vietnam Medical Instrument JSC (JVC)?
Earnings per share at Japan Vietnam Medical Instrument JSC are growing +454% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Japan Vietnam Medical Instrument JSC in the live analysis

One click puts Japan Vietnam Medical Instrument JSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.